Profile of sexual and genitourinary treatment-emergent adverse events associated with atomoxetine treatment: A pooled analysis

Drug Safety

Volumn 36, Issue 8, 2013, Pages 663-671

  Camporeale, Angelo ^a   Day, Kathleen Ann ^a   Ruff, Dustin ^a   Arsenault, Jody ^b   Williams, David ^b   Kelsey, Douglas K ^a  

^a ELI LILLY AND COMPANY   (United States)

^b SYNEOS HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; PLACEBO;

ADULT; AGED; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DRUG EFFECT; DRUG INFORMATION; DYSURIA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FEMALE; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX RATIO; TREATMENT DURATION; URINARY HESITATION;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; FEMALE; FEMALE UROGENITAL DISEASES; HUMANS; MALE; MALE UROGENITAL DISEASES; MIDDLE AGED; PROPYLAMINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TIME FACTORS;

EID: 84881192002     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0074-2     Document Type: Article

References (31)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington, DC: American Psychiatric Press; 2000.
2. Wender PH, Wolf LE, Wasserstein J. Adults with ADHD: an overview. Ann N Y Acad Sci. 2001;931:1-16.
3. Wilens TE, Dodson W. A clinical perspective of attention-deficit/ hyperactivity disorder into adulthood. J Clin Psychiatry. 2004;65(10):1301-13.
4. Kessler RC, Coccaro EF, Fava M, et al. The prevalence and correlates of DSM-IV intermittent explosive disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006;63(6):669-78.
5. Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402-9.
6. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-23.
7. Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63(Suppl. 12):10-5.
8. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5):E83.
9. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159(11):1896-901.
10. Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology. 2005;65(12):1941-9.
11. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;114(1):e1-8.
12. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53(2):112-20.
13. Adler LA, Spencer T, Brown TE, et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol. 2009;29(1):44-50.
14. Young JL, Sarkis E, Qiao M, et al. Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol. 2011;34(2):51-60.
15. Durell T, Adler L, Wilens T, et al. Atomoxetine treatment for ADHD: younger adults compared with older adults. J Atten Disord. 2010;13(4):401-6.
16. Wietecha LA, Williams DW, Herbert M, et al. Atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(6):719-30.
17. Adler LA, Liebowitz M, Kronenberger W, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety. 2009;26(3):212-21.
18. ® (atomoxetine). US prescribing information. Indianapolis: Eli Lilly and Company; 2011.
19. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699-711.
20. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 1993;52(12):1023-9.
21. Tatsumi M, Groshan K, Blakely RD, et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340(2-3):249-58.
22. Gehlert DR, Schober DA, Gackenheimer SL. Comparison of (R)-[3H]tomoxetine and (R/S)-[3H]nisoxetine binding in rat brain. J Neurochem. 1995;64(6):2792-800.
23. Wong DT, Threlkeld PG, Best KL, et al. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther. 1982;222(1):61-5.
24. Wilens TE. Mechanism of action of agents used in attention-deficit/ hyperactivity disorder. J Clin Psychiatry. 2006;67(Suppl. 8):32-8.
25. Sumner CR, Schuh KJ, Sutton VK, et al. Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis. J Child Adolesc Psychopharmacol. 2006;16(6):699-711.
26. Viktrup L, Pangallo BA, Detke MJ, et al. Urinary side effects of duloxetine in the treatment of depression and stress urinary incontinence. Prim Care Companion J Clin Psychiatry. 2004;6(2):65-73.
27. Scharko AM. Selective serotonin reuptake inhibitor-induced sexual dysfunction in adolescents: a review. J Am Acad Child Adolesc Psychiatry. 2004;43(9):1071-9.
28. ® (methylphenidate HCl) extended-release tablets CII. US prescribing information. Titusville: Ortho-McNeil-Janssen Pharmaceuticals; 2010.
29. Vyvanse (lisdexamfetamine dimesylate) capsule. US prescribing information. Wayne: Shire LLC; 2012.
30. Adderall (dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate) tablet. US prescribing information. Wayne: Shire US Inc.; 2006.
31. Edronax (reboxetine) 4 mg tablets: summary of product characteristics. Kent: Pharmacia Limited; 2011.